Cargando…
Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies
INTRODUCTION: “Re-infection” with COVID-19 is a growing concern; re-infection cases have reported worldwide. However, the clinical characteristics of SARS-CoV-2 re-infection, including the levels and role of anti-SARS-CoV-2 Spike protein IgG antibodies and the half-maximal concentration (IC(50)) of...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064832/ https://www.ncbi.nlm.nih.gov/pubmed/33962861 http://dx.doi.org/10.1016/j.jiac.2021.04.017 |
_version_ | 1783682218692968448 |
---|---|
author | Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Tsuchiya, Kiyoto Miura, Kenji Sairenji, Yu Kinoshita, Noriko Ujiie, Mugen Kutsuna, Satoshi Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio |
author_facet | Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Tsuchiya, Kiyoto Miura, Kenji Sairenji, Yu Kinoshita, Noriko Ujiie, Mugen Kutsuna, Satoshi Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio |
author_sort | Inada, Makoto |
collection | PubMed |
description | INTRODUCTION: “Re-infection” with COVID-19 is a growing concern; re-infection cases have reported worldwide. However, the clinical characteristics of SARS-CoV-2 re-infection, including the levels and role of anti-SARS-CoV-2 Spike protein IgG antibodies and the half-maximal concentration (IC(50)) of neutralizing antibodies remain unknown. METHODS: Both the epidemiological and clinical information has been collected during two episodes of COVID-19 in a patient. Laboratory results, including RT-PCR, Ct values, anti-SARS-CoV-2 Spike protein IgG antibodies, and the IC(50) of neutralizing antibodies levels were analyzed on the patient. RESULTS: The patient was a 58-year-old man who developed moderate COVID-19 pneumonia with oxygen demand (cannula 2 L/min) in the first episode. By day 30, he recuperated and was discharged after testing negative for SARS-CoV-2. After two and a half months, his three family members showed COVID-19 symptoms and tested positive for SARS-CoV-2. He tested positive for SARS-CoV-2 once again and was asymptomatic (the second episode). The IC(50) of neutralizing antibodies against SARS-CoV-2 greatly increased from 50.0 μg/mL (after the first episode) to 14.8 μg/mL (after the second episode), and remained strongly reactive (20.1 μl/mL) after 47 days of the second episode. CONCLUSIONS: Epidemiological, clinical, and serological analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Our results suggest that SARS-CoV-2 re-infection may manifest as asymptomatic with increased neutralizing antibody levels. Further studies such as the virus characteristics, immunology, and epidemiology on SARS-CoV-2 re-infection are needed. |
format | Online Article Text |
id | pubmed-8064832 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80648322021-04-26 Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Tsuchiya, Kiyoto Miura, Kenji Sairenji, Yu Kinoshita, Noriko Ujiie, Mugen Kutsuna, Satoshi Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio J Infect Chemother Original Article INTRODUCTION: “Re-infection” with COVID-19 is a growing concern; re-infection cases have reported worldwide. However, the clinical characteristics of SARS-CoV-2 re-infection, including the levels and role of anti-SARS-CoV-2 Spike protein IgG antibodies and the half-maximal concentration (IC(50)) of neutralizing antibodies remain unknown. METHODS: Both the epidemiological and clinical information has been collected during two episodes of COVID-19 in a patient. Laboratory results, including RT-PCR, Ct values, anti-SARS-CoV-2 Spike protein IgG antibodies, and the IC(50) of neutralizing antibodies levels were analyzed on the patient. RESULTS: The patient was a 58-year-old man who developed moderate COVID-19 pneumonia with oxygen demand (cannula 2 L/min) in the first episode. By day 30, he recuperated and was discharged after testing negative for SARS-CoV-2. After two and a half months, his three family members showed COVID-19 symptoms and tested positive for SARS-CoV-2. He tested positive for SARS-CoV-2 once again and was asymptomatic (the second episode). The IC(50) of neutralizing antibodies against SARS-CoV-2 greatly increased from 50.0 μg/mL (after the first episode) to 14.8 μg/mL (after the second episode), and remained strongly reactive (20.1 μl/mL) after 47 days of the second episode. CONCLUSIONS: Epidemiological, clinical, and serological analyses confirmed that the patient had re-infection instead of persistent viral shedding from first infection. Our results suggest that SARS-CoV-2 re-infection may manifest as asymptomatic with increased neutralizing antibody levels. Further studies such as the virus characteristics, immunology, and epidemiology on SARS-CoV-2 re-infection are needed. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2021-07 2021-04-24 /pmc/articles/PMC8064832/ /pubmed/33962861 http://dx.doi.org/10.1016/j.jiac.2021.04.017 Text en © 2021 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Original Article Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Tsuchiya, Kiyoto Miura, Kenji Sairenji, Yu Kinoshita, Noriko Ujiie, Mugen Kutsuna, Satoshi Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title | Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title_full | Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title_fullStr | Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title_full_unstemmed | Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title_short | Asymptomatic COVID-19 re-infection in a Japanese male by elevated half-maximal inhibitory concentration (IC(50)) of neutralizing antibodies |
title_sort | asymptomatic covid-19 re-infection in a japanese male by elevated half-maximal inhibitory concentration (ic(50)) of neutralizing antibodies |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064832/ https://www.ncbi.nlm.nih.gov/pubmed/33962861 http://dx.doi.org/10.1016/j.jiac.2021.04.017 |
work_keys_str_mv | AT inadamakoto asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT ishikanemasahiro asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT teradamari asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT matsunagaakihiro asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT maedakenji asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT tsuchiyakiyoto asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT miurakenji asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT sairenjiyu asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT kinoshitanoriko asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT ujiiemugen asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT kutsunasatoshi asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT ishizakayukihito asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT mitsuyahiroaki asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies AT ohmagarinorio asymptomaticcovid19reinfectioninajapanesemalebyelevatedhalfmaximalinhibitoryconcentrationic50ofneutralizingantibodies |